Mental health, bias, and trauma shape sexual health visits, and histories should assess function, not just risk, according to Sameena Rahman, MD.
|Videos|August 25, 2020
Addressing health care disparities: A simple way to better serve your patients
Vanessa L. Rogers, MD, shares her expert insight into ways practitioners can address health care disparities in their area and provide patients with better care.
Advertisement
"Disparities you find depending on which zip code you live in are dramatic," says Dr. Rogers.
Watch the full,
Advertisement
Related to this article
Samples from a large UK screening trial supported validation of the investigational Evident ovarian cancer test, according to Dawn Mattoon, PhD.
Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
In the premiere episode of Mind, Body, & the Pause, Soma Mandal, MD, is joined by Manisha Parulekar, MD, and Jocelyn Carlo, MD, FACOG, to discuss the stages of the menopause transition.
This FAQ summarizes a Special Report discussion on off-label testosterone dosing, application, cost, and lab monitoring in women.
This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Centers for Medicare, Medicaid Services includes AMA's obstetric codes in 2027 fee schedule
2
FAQ: How is off-label testosterone dosed and monitored in women?
3
Q&A: Soma Mandal, MD, MSCP, on FDA boxed warning removals for MHT
4
FAQ: Who is a candidate for testosterone therapy in women?
5